RESUMO
We present an unusual case of a 60 year old male who was noted to have primary hypothyroidism and decreased consciousness which did not respond to Levothyroxine. Further investigations revealed a diagnosis of Hashimoto's Encephalopathy which responded well to steroids. We describe the case in detail and discuss the available relevant literature on this topic.
Assuntos
Encefalopatias/complicações , Encefalopatias/diagnóstico , Estado de Consciência , Doença de Hashimoto/complicações , Doença de Hashimoto/diagnóstico , Hipotireoidismo/complicações , Hipotireoidismo/diagnóstico , Tiroxina/uso terapêutico , Encefalopatias/tratamento farmacológico , Diagnóstico Diferencial , Eletroencefalografia/métodos , Encefalite , Glucocorticoides/uso terapêutico , Doença de Hashimoto/tratamento farmacológico , Humanos , Hipotireoidismo/tratamento farmacológico , Masculino , Metilprednisolona/uso terapêutico , Pessoa de Meia-Idade , Resultado do TratamentoRESUMO
BACKGROUND: Orlistat has been shown to increase adiponectin and reduce progression to type 2 diabetes in obese Caucasians. Some effects of orlistat are thought to be independent of weight loss by altering gut flora and the production of endotoxin lipopolysaccharide (LPS). We studied the effect of dietary treatment with and without orlistat in South Asian individuals with impaired glucose tolerance (IGT) on adiponectin and inflammatory markers including LPS. METHODS: South Asian individuals were randomised to either dietary treatment with orlistat or dietary treatment alone. At the end of 12 months, a comparison was made between the two groups for differences in anthropomorphic measurements and serum markers. RESULTS: Three hundred and five individuals underwent oral glucose tolerance test of whom 40 had IGT. Complete baseline and 1-year data was available for 31 patients. After 1 year, patients in the orlistat group demonstrated a greater but insignificant decrease in weight (4.5 +/- 0.1 kg), and a significant increase in adiponectin (6.73 +/- 3.2 microg/ml) and decrease in LPS (4.55 +/- 1.98 EU/ml) compared with- the diet-alone group. In the orlistat group the reduction in LPS was correlated with the increase in adiponectin (p < 0.005). CONCLUSION: The increase in adiponectin levels in the orlistat group would suggest that orlistat may reduce the progression to type 2 diabetes in South Asian individuals by raising serum adiponectin. The finding that LPS levels are also reduced by orlistat and that this reduction correlates with the increase in adiponectin raises the possibility that the increase in adiponectin may be mediated via an effect on LPS levels.
Assuntos
Adipocinas/sangue , Intolerância à Glucose/tratamento farmacológico , Lactonas/uso terapêutico , Lipopolissacarídeos/sangue , Adulto , Terapia Combinada , Feminino , Seguimentos , Intolerância à Glucose/sangue , Intolerância à Glucose/dietoterapia , Humanos , Lipídeos/sangue , Masculino , OrlistateRESUMO
A popular hypothesis for the greater prevalence of type 2 diabetes and cardiovascular disease in UK south Asians is that they have an increased susceptibility of developing insulin resistance in response to certain environmental factors, including obesity and adoption of a sedentary lifestyle. Insulin resistance is postulated as a central feature of the metabolic syndrome, culminating in type 2 diabetes, atherosclerotic vascular disease and CHD; a pathway potentially accelerated by migration/urbanisation. We describe and compare the prevalence of type 2 diabetes, cardiovascular disease and their associated risk factors in UK south Asian and white Caucasian populations to determine possible reasons for the increased preponderance of these diseases in south Asians, and highlight key evidence for optimal risk factor management. Finally, we describe a UK community-based programme that attempts to reduce the morbidity and mortality from type 2 diabetes and cardiovascular disease in south Asians through a new approach to management.
Assuntos
Povo Asiático/estatística & dados numéricos , Doenças Cardiovasculares/epidemiologia , Diabetes Mellitus Tipo 2/epidemiologia , Angiopatias Diabéticas/epidemiologia , Adulto , Distribuição por Idade , Diabetes Mellitus Tipo 2/genética , Angiopatias Diabéticas/genética , Predisposição Genética para Doença , Humanos , Pessoa de Meia-Idade , Prevalência , Fatores de Risco , Reino Unido/epidemiologiaRESUMO
We present a case of a 29-year-old woman with known Type 1 diabetes who presented with diabetic ketoacidosis (DKA). Despite appropriate treatment and initial improvement, 12 h after initiation of treatment she deteriorated rapidly and developed pulmonary oedema, cerebral oedema and multiple infarctions of the brain and cervical spinal cord. This resulted in spastic quadraparesis and she has remained wheelchair-bound. These complications of DKA are rare and unpredictable. In this case report we discuss the proposed aetiologies of these complications with reference to our case report and highlight the importance of vigilance for early signs of these complications during the treatment of all patients with DKA.
Assuntos
Edema Encefálico/complicações , Infarto Encefálico/complicações , Cetoacidose Diabética/complicações , Edema Pulmonar/complicações , Medula Espinal/irrigação sanguínea , Adulto , Vértebras Cervicais , Diabetes Mellitus Tipo 1/complicações , Feminino , Humanos , Infarto/complicações , Quadriplegia/etiologiaRESUMO
A 24 year old white woman presented with sudden onset of flaccid quadriparesis and hypokalaemia. She was later found to be thyrotoxic. Paralysis resolved with potassium supplements, and after initiation of antithyroid medication she had no further episodes of hypokalaemic paralysis. To the best of the authors' knowledge, and after a Medline search, thyrotoxic periodic paralysis has not been described previously in a white woman.